Search

Your search keyword '"Bogaerts, Jan"' showing total 308 results

Search Constraints

Start Over You searched for: Author "Bogaerts, Jan" Remove constraint Author: "Bogaerts, Jan"
308 results on '"Bogaerts, Jan"'

Search Results

4. Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer

5. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

6. Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.

7. Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial

8. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

9. Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group.

11. Societal challenges of precision medicine: Bringing order to chaos

13. Supplementary Data1 from Meta-Analysis of the Test–Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response

16. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

19. Meta-Analysis of the Test–Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response

20. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial

22. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

23. Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance

32. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial

41. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer

43. Total dose and displacement damage effects in a radiation-hardened CMOS APS

44. 70-Gene Signature as an Aid to Treatment Decisions in Early Breast Cancer: Updated Results MINDACT

48. Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma-In-Situ: Ten-Year Results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853—A Study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group

Catalog

Books, media, physical & digital resources